Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Metformin in Gestational Diabetes Mellitus (MetGDM)
This study is currently recruiting participants.
Verified by K. Marcinkowski University of Medical Sciences, May 2008
Sponsored by: K. Marcinkowski University of Medical Sciences
Information provided by: K. Marcinkowski University of Medical Sciences
ClinicalTrials.gov Identifier: NCT00681460
  Purpose

Gestational diabetes (GDM) is a condition that manifests as high blood sugar levels (hyperglycemia) during pregnancy in previously healthy women. It develops as a result of increased maternal body's resistance to insulin - a major hormone that allows for utilisation of glucose (sugar taken in with food) within cells. It was found out that GDM occurs more frequently in overweight women but also in women with a history of certain conditions such as polycystic ovary syndrome (PCOS). Usually, GDM disappears after pregnancy is completed but it is associated with some serious hazards for women and her unborn child, if untreated properly. Diet is a first-choice treatment but sometimes insulin therapy must be initiated if keeping a diet alone is not enough to maintain blood sugar within recommended values. Insulin therapy is effective but it requires several injections during each day and insulin is a strong acting hypoglycemic agent that may induce rapid falls in blood sugar, also dangerous for mother and unborn child.

In our study, we would like to investigate if metformin that is a commonly used hypoglycemic drug can be effectively used for GDM treatment. Metformin has been used successfully for a long time to treat type 2 diabetes mellitus and PCOS and, according to current data, it is not dangerous neither for mother nor for baby when used during gestation.


Condition Intervention
Diabetes, Gestational
Insulin Resistance
Drug: human recombined insulin
Drug: metformin

MedlinePlus related topics: Diabetes
Drug Information available for: Insulin Metformin Metformin hydrochloride
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Parallel Assignment, Efficacy Study
Official Title: Effects of Insulin and/or Metformin Treatment on Perinatal Outcome and Metabolic Parameters in Women With Gestational Diabetes Mellitus: Prospective Randomized Trial.

Further study details as provided by K. Marcinkowski University of Medical Sciences:

Primary Outcome Measures:
  • newborn weight [ Time Frame: first hour of life ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • parameters of metabolic control in mother and newborn, insulin resistance, inflammatory reaction, oxidative stress, fetal growth, [ Time Frame: during pregnancy and up to twelve hours after delivery ] [ Designated as safety issue: No ]

Estimated Enrollment: 180
Study Start Date: May 2008
Estimated Study Completion Date: May 2011
Estimated Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1: Active Comparator
gestational diabetes, insulin therapy
Drug: human recombined insulin
multiple injections protocol (functional intensive insulin therapy), variable doses following dietary conditions and current metabolic status
2: Experimental
gestational diabetes, metformin therapy
Drug: metformin
pills given orally twice up to three times a day, a total daily dosage 1000-2400 mg
3: No Intervention
healthy controls, no treatment

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • diabetes diagnosed during pregnancy
  • single pregnancy
  • ineffective diet therapy

Exclusion Criteria:

  • pregestational diabetes
  • fetal malformation
  • multiple pregnancy
  • contraindications to metformin therapy (liver or kidney disease)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00681460

Contacts
Contact: Hanna Mitkowska Wozniak, MD, PhD +48 601 88 60 00 hanna.mitkowska@onet.eu
Contact: Agnieszka Zawiejska, MD, PhD +48 600 22 33 06 agazaw@poczta.onet.pl

Locations
Poland
Div of Obstetrics and Women's Diseases, Dept of Obstetrics and Gynecology, K Marcinkowski Univ of Med Sciences Recruiting
Poznan, Poland, 60-535
Sponsors and Collaborators
K. Marcinkowski University of Medical Sciences
Investigators
Study Chair: Jacek Brazert, MD.PhD.prof K Marcinkowski University of Med Sciences, Poznan, Poland
Study Director: Antoni J Duleba, MD.prof University of California at Davis, Sacramento, CA, USA
Principal Investigator: Hanna Mitkowska Wozniak, MD.PhD K Marcinkowski University of Med Sciences, Poznan, Poland
  More Information

Responsible Party: K. Marcinkowski University of Medical Sciences ( Div.of Obstet.&Womens Disease Dep. of Obstet.&Gyn., Hanna Mitkowska Wozniak )
Study ID Numbers: KMUMS 705/07
Study First Received: May 19, 2008
Last Updated: May 20, 2008
ClinicalTrials.gov Identifier: NCT00681460  
Health Authority: Poland: Ministry of Health

Keywords provided by K. Marcinkowski University of Medical Sciences:
gestational diabetes
birth weight
fetal growth
insulin resistance
oxidative stress
inflammatory reaction
Fetal Development

Study placed in the following topic categories:
Birth Weight
Metabolic Diseases
Pregnancy Complications
Metformin
Diabetes Mellitus
Stress
Endocrine System Diseases
Diabetes, Gestational
Insulin
Inflammation
Body Weight
Hyperinsulinism
Endocrinopathy
Insulin Resistance
Glucose Metabolism Disorders
Metabolic disorder

Additional relevant MeSH terms:
Hypoglycemic Agents
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 13, 2009